Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Evaluation Of The Diffusion Coefficient For Controlled Release Of Oxytetracycline From Alginate/chitosan/poly(ethylene Glycol) Microbeads In Simulated Gastrointestinal Environments

Diffusion studies of OTC (oxytetracycline) entrapped in microbeads of calcium alginate, calcium alginate coacervated with chitosan (of high, medium and low viscosity) and calcium alginate coacervated with chitosan of low viscosity, covered with PEG [poly(ethylene glycol) of molecular mass 2, 4.6 and 10 kDa, were carried out at 37 ± 0.5 ̊C, in pH 7.4 and pH 1.2 buffer solutions - conditions similar to those found in the gastrointestinal system. The diffusion coefficient, or diffusivity (D), of OTC was calculated by equations provided by Crank [(1975) Mathematics in Diffusion, p. 85, Clarendon Press, Oxford] for diffusion, which follows Fick's [(1855) Ann. Physik (Leipzig) 170, 59] second law, considering the diffusion from the inner parts to the surface of the microbeads. The least-squares and the Newton-Raphson [Carnahan, Luther and Wilkes (1969) Applied Numerical Methods, p. 319, John Wiley & Sons, New York] methods were used to obtain the diffusion coefficients. The microbead swelling at pH 7.4 and OTC diffusion is classically Fickian, suggesting that the OTC transport, in this case, is controlled by the exchange rates of free water and relaxation of calcium alginate chains. In case of acid media, it was observed that the phenomenon did not follow Pick's law, owing, probably, to the high solubility of the OTC in this environment. It was possible to modulate the release rate of OTC in several types of microbeads. The presence of cracks formed during the process of drying the microbeads was observed by scanning electron microscopy.403243253Mogul, M.G., Akin, H., Hasirci, N., Trantolo, D.J., Gresser, J.D., Wise, D.L., (1996) Resour. Conserv. Recycl., 16, pp. 289-320Buonocore, G.G., Del Mobile, M.A., Panizza, A., Corbo, M.R., Nicolais, L., (2003) J. Controlled Release, 90, pp. 97-107Hiratani, H., Alvarez-Lorenzo, C., (2004) Biomaterials, 25, pp. 1105-1113Coombes, A.G.A., Rizzi, S.C., Williamson, M., Barralet, J.E., Downes, S., Wallace, W.A., (2004) Biomaterials, 25, pp. 315-325Mark, H.F., (1988) Encyclopedia of Polymer Science and Engineering, pp. 164-186. , (Mark, H. F, ed.), John Wiley & Sons, New YorkPark, H., Park, K., (1992) Polymers of Biological and Biomedical Significance, pp. 3-15. , (Shalaby, S. W., ed.), American Chemical Society, WashingtonPeppas, N.A., (1987) Hydrogels in Medicine and Pharmacy, , CRC Press, Boca RatonTakka, S., Acartürk, F., (1999) J. Microencapsulation, 16, pp. 275-290Acartürk, F., Takka, S., (1999) J. Microencapsulation, 16, pp. 291-301Draget, K.I., Steinsväg, K., Onsøyen, E., Smidsrød, (1998) Carbohydr. Polym., 35, pp. 1-6Bodmeier, R., Oh, K., Pramar, Y., (1989) Drug Dev. Ind. Pharm., 15, pp. 1475-1494Chandy, T., Sharma, C.P., (1993) Biomaterials, 14, pp. 939-944Mi, F., Wong, T., Shyu, S., Chang, S., (1999) J. Appl. Polym. Sci., 71, pp. 747-759Gupta, K.C., Ravi Kumar, M.N.V., (2000) Biomaterials, 21, pp. 1115-1119Daly, M., Knorr, D., (1988) Biotechnol. Prog., 4, pp. 76-81Huguet, M.L., Dellacherie, E., (1996) Process Biochem., 31, pp. 745-751Huguet, M., Neufeld, L.R.J., Dellacherie, E., (1996) Process Biochem., 31, pp. 347-353Polk, A., Amsden, B., De Yao, K., Peng, T., Goosen, M.F.A., (1994) J. Pharm. Sci., 83, pp. 178-185Mi, F., Sung, H., Shyu, S., (2002) Carbohydr. Polym., 48, pp. 61-72Vandenberg, G.W., De La Noüe, J., (2001) J. Microencapsulation, 18, pp. 433-441Gåserød, O., Smidsrød, O., Skjäk-Braek, G., (1998) Biomaterials, 19, pp. 1815-1825Sezer, A.D., Akbuga, J., (1999) J. Microencapsulation, 16, pp. 195-203Gåserød, O., Sannes, A., Skjåk-Braek, G., (1999) Biomaterials, 20, pp. 773-783Sezer, A.D., Akbuga, J., (1999) J. Microencapsulation, 16, pp. 687-696De, S., Robinson, D., (2003) J. Controlled Release, 89, pp. 101-112González-Rodriguez, M.L., Holgado, M.A., Sánchez-Lafuente, C., Rabasco, A.M., Fini, A., (2002) Int. J. Pharm., 232, pp. 225-234Lee, O., Ha, B., Park, S., Lee, Y., (1997) Macromol. Chem. Phys., 198, pp. 2971-2976Wheatley, M.A., Chang, M., Park, E., Langer, R., (1991) J. Appl. Polym. Sci., 43, pp. 2123-2135Lee, K.Y., Park, W.H., Ha, W.S., (1997) J. Appl. Polym. Sci., 63, pp. 425-432Hari, P.R., Chandy, T., Sharma, C.P., (1996) J. Appl. Polym. Sci., 59, pp. 1795-1801Chandy, T., Mooradian, D.L., Rao, G.H.R., (1998) J. Appl. Polym. Sci., 70, pp. 2143-2153Chandy, T., Mooradian, D.L., Rao, G.H.R., (1999) Artif. Organs, 23, pp. 894-903(1978) Kirk-Othmer Encycl. Chem. Technol., 3, pp. 65-79Blackwood, R.K., English, A.R., (1970) Adv. Appl. Microbiol., 13, pp. 237-266Pick, A., (1855) Ann. Physik (Leipzig), 170, p. 59Crank, J., (1975) Mathematics in Diffusion, p. 85. , Clarendon Press, OxfordCarnahan, B., Luther, H.A., Wilkes, J.O., (1969) Applied Numerical Methods, p. 319. , John Wiley & Sons, New YorkSignini, R., Campana Filho, S.P., (1999) Polym. Bull., 42, pp. 159-166Grigolon, L.B., Azevedo, A., Santos, R.R., Franco, T.T., (2001) Chitin Enzymology 2001, pp. 415-421. , (Muzzarelli, R. A. A., ed.), Atec, GrottamareGrasdalen, H., Larsen, B., Smidsrod, O., (1979) Carbohydr. Res., 68, pp. 23-31Signini, R., Campana Filho, S.P., (1998) Polím. Ciênc. Tecnol. (São Carlos), 4, pp. 63-68Signini, R., Campana Filho, S.P., (2001) Polím. Ciênc. Tecnol., 11, pp. 58-64Grasdalen, H., (1983) Carbohydr. Res., 118, pp. 255-260Brazel, C.S., Peppas, N.A., (1999) Polymer, 40, pp. 3383-3398Hoffman, A.S., (2002) Adv. Drug Deliv. Rev., 43, pp. 3-12Masaro, L., Zhu, X.X., (1999) Prog. Polym. Sci., 24, pp. 731-775Ritger, P.L., Peppas, N., (1987) J. Controlled Release, 5, pp. 37-42Tanaka, H., Matsumura, M., Veliky, A., (1984) Biotechnol. Bioeng., 26, pp. 53-58Martinsen, A., Starrød, I., Skjak-Braek, G., (1992) Biotechnol. Bioeng., 39, pp. 186-19

Vascular complications of black patients with type 2 diabetes mellitus in Southern Brazil

Ethnicity has been shown to be associated with micro- and macrovascular complications of diabetes in European and North American populations. We analyzed the contribution of ethnicity to the prevalence of micro- and macrovascular complications in Brazilian subjects with type 2 diabetes attending the national public health system. Data from 1810 subjects with type 2 diabetes (1512 whites and 298 blacks) were analyzed cross-sectionally. The rates of ischemic heart disease, peripheral vascular disease, stroke, distal sensory neuropathy, and diabetic retinopathy were assessed according to self-reported ethnicity using multiple logistic regression models. Compared to whites, black subjects [odds ratio = 1.72 (95%CI = 1.14-2.6)] were more likely to have ischemic heart disease when data were adjusted for age, sex, fasting plasma glucose, HDL cholesterol, hypertension, smoking habit, and serum creatinine. Blacks were also more likely to have end-stage renal disease [3.2 (1.7-6.0)] and proliferative diabetic retinopathy [1.9 (1.1-3.2)] compared to whites when data were adjusted for age, sex, fasting plasma glucose, HDL cholesterol, hypertension, and smoking habit. The rates of peripheral vascular disease, stroke and distal sensory neuropathy did not differ between groups. The higher rates of ischemic heart disease, end-stage renal disease and proliferative diabetic retinopathy in black rather than in white Brazilians were not explained by differences in conventional risk factors. Identifying which aspects of ethnicity confer a higher risk for these complications in black patients is crucial in order to understand why such differences exist and to develop more effective strategies to reduce the onset and progression of these complications